中国麻风皮肤病杂志 ›› 2023, Vol. 39 ›› Issue (6): 397-402.doi: 10.12144/zgmfskin202306397

• 论著 • 上一篇    下一篇

托法替布治疗掌跖脓疱病三例并文献复习

王天姿,陆继良,刘永霞,田洪青   

  1. 山东第一医科大学附属皮肤病医院（山东省皮肤病医院），山东省皮肤病性病防治研究所，山东济南，250022
  • 出版日期:2023-06-15 发布日期:2023-05-18

Three cases with palmoplantar pustulosis successfully treated by tofacitinib

WANG Tianzi, LU Jiliang, LIU Yongxia, TIAN Hongqing   

  1. Shandong Provincial Hospital for Skin Disease & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2023-06-15 Published:2023-05-18

PDF (PC)

129

摘要： 掌跖脓疱病的传统治疗包括口服阿维A、环孢菌素A及甲氨蝶呤等，常因不良反应而使用受限。JAK抑制剂通过抑制JAK-STAT通路，影响一系列细胞因子的功能，发挥免疫调节作用，在银屑病、特应性皮炎等炎症性皮肤病中的临床疗效观察均获得了令人满意的结果。本文报道JAK抑制剂托法替布有效治疗掌跖脓疱病3例并进行文献复习。

关键词: 托法替布, 掌跖脓疱病, JAK抑制剂

Abstract: The traditional oral drugs of palmoplantar pustulosis includes acitretin, methotrexate, cyclosporine A, the use of which are often limited due to adverse reactions. Jak inhibitors such as tofacitinib could affect a series of cytokines by inhibiting the JAK-STAT pathway, and play an immunomodulatory role. The clinical efficacy of JAK inhibitors in psoriasis and atopic dermatitis has been confirmed. We reporte three cases of palmoplantar pustulosis successfully treated with tofacitinib and reviewed the relevant literature.

Key words: tofacitinib, palmoplantar pustulosis, JAK inhibitors